Top Markets
Coin of the day
Nextgen Biomed Ltd Nextgen Biomed Ltd

Nextgen Biomed Ltd

NXGN
Rank in Stocks #37893
Nextgen Biomed Ltd focuses on developing external dermatological treatments for... Nextgen Biomed Ltd focuses on developing external dermatological treatments for psoriasis. The company, which was established in 1990, originally operated under the name Sela Group.Com Ltd. before rebranding as Nextgen Biomed Ltd in February 2010. Its operations are headquartered in Tel Aviv, Israel.
Share Price
$0.14896012
Last synced: 2026-02-16
Market Cap
$1.37M
Change (1 day)
-2.89%
Change (1 year)
-19.65%
Country
IL
Trade Nextgen Biomed Ltd (NXGN)

Category

P/E ratio for Nextgen Biomed Ltd (NXGN)
P/E ratio as of 2026 TTM: 0
According to Nextgen Biomed Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nextgen Biomed Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
44.58 -
US
30.38 -
FR
- -
JP
41.93 -
US
- -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.